Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 321

1.

The Ashitaba (Angelica keiskei) chalcones 4-hydroxyderricin and xanthoangelol suppress melanomagenesis by targeting BRAF and PI3-K.

Zhang T, Wang Q, Fredimoses M, Gao G, Wang K, Chen H, Wang T, Oi N, Zykova T, Reddy K, Yao K, Ma W, Chang X, Lee MH, Rathore MG, Bode AM, Ashida H, Dong Z.

Cancer Prev Res (Phila). 2018 Jul 6. pii: canprevres.0092.2018. doi: 10.1158/1940-6207.CAPR-18-0092. [Epub ahead of print]

PMID:
29980517
2.

Targeting PRPK and TOPK for skin cancer prevention and therapy.

Roh E, Lee MH, Zykova TA, Zhu F, Nadas J, Kim HG, Bae KB, Li Y, Cho YY, Curiel-Lewandrowski C, Einspahr J, Dickinson SE, Bode AM, Dong Z.

Oncogene. 2018 Jun 14. doi: 10.1038/s41388-018-0350-9. [Epub ahead of print]

PMID:
29904102
3.

Addressing the challenges of applying precision oncology.

Shin SH, Bode AM, Dong Z.

NPJ Precis Oncol. 2017 Sep 4;1(1):28. doi: 10.1038/s41698-017-0032-z. eCollection 2017. Review.

4.

DNMT1 mediates metabolic reprogramming induced by Epstein-Barr virus latent membrane protein 1 and reversed by grifolin in nasopharyngeal carcinoma.

Luo X, Hong L, Cheng C, Li N, Zhao X, Shi F, Liu J, Fan J, Zhou J, Bode AM, Cao Y.

Cell Death Dis. 2018 May 23;9(6):619. doi: 10.1038/s41419-018-0662-2.

5.

Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies.

Li H, Hu J, Luo X, Bode AM, Dong Z, Cao Y.

Cancer Sci. 2018 Jul;109(7):2101-2108. doi: 10.1111/cas.13634. Epub 2018 Jun 13. Review.

6.

TRAF1 Is Critical for Regulating the BRAF/MEK/ERK Pathway in Non-Small Cell Lung Carcinogenesis.

Wang Q, Gao G, Zhang T, Yao K, Chen H, Park MH, Yamamoto H, Wang K, Ma W, Malakhova M, Bode AM, Dong Z.

Cancer Res. 2018 Jul 15;78(14):3982-3994. doi: 10.1158/0008-5472.CAN-18-0429. Epub 2018 May 10.

PMID:
29748372
7.

Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy.

Tan Z, Xiao L, Tang M, Bai F, Li J, Li L, Shi F, Li N, Li Y, Du Q, Lu J, Weng X, Yi W, Zhang H, Fan J, Zhou J, Gao Q, Onuchic JN, Bode AM, Luo X, Cao Y.

Theranostics. 2018 Mar 22;8(9):2329-2347. doi: 10.7150/thno.21451. eCollection 2018.

8.

Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma In Vitro and Patient-Derived Xenografts In Vivo.

Song M, Liu X, Liu K, Zhao R, Huang H, Shi Y, Zhang M, Zhou S, Xie H, Chen H, Li Y, Zheng Y, Wu Q, Liu F, Li E, Bode AM, Dong Z, Lee MH.

Mol Cancer Ther. 2018 Jul;17(7):1540-1553. doi: 10.1158/1535-7163.MCT-17-0823. Epub 2018 Apr 25.

PMID:
29695636
9.

RSK2 is required for TRAF6 phosphorylation-mediated colon inflammation.

Yao K, Lee SY, Peng C, Lim DY, Yamamoto H, Ryu J, Lim TG, Chen H, Jin G, Zhao Z, Han Y, Ma WY, Bode AM, Dong Z.

Oncogene. 2018 Jun;37(26):3501-3513. doi: 10.1038/s41388-018-0167-6. Epub 2018 Mar 22.

PMID:
29563609
10.

Targeting PRPK Function Blocks Colon Cancer Metastasis.

Zykova T, Zhu F, Wang L, Li H, Lim DY, Yao K, Roh E, Yoon SP, Kim HG, Bae KB, Wen W, Shin SH, Nadas J, Li Y, Ma W, Bode AM, Dong Z.

Mol Cancer Ther. 2018 May;17(5):1101-1113. doi: 10.1158/1535-7163.MCT-17-0628. Epub 2018 Feb 26.

PMID:
29483219
11.

IDH2 is a novel diagnostic and prognostic serum biomarker for non-small-cell lung cancer.

Li JJ, Li R, Wang W, Zhang B, Song X, Zhang C, Gao Y, Liao Q, He Y, You S, Tan Z, Luo X, Li Y, Tang M, Weng X, Yi W, Peng S, Liu S, Tan Y, Bode AM, Cao Y.

Mol Oncol. 2018 May;12(5):602-610. doi: 10.1002/1878-0261.12182. Epub 2018 Mar 25.

12.

Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice.

Blohm-Mangone K, Burkett NB, Tahsin S, Myrdal PB, Aodah A, Ho B, Janda J, McComas M, Saboda K, Roe DJ, Dong Z, Bode AM, Petricoin EF 3rd, Calvert VS, Curiel-Lewandrowski C, Alberts DS, Wondrak GT, Dickinson SE.

Cancer Prev Res (Phila). 2018 May;11(5):265-278. doi: 10.1158/1940-6207.CAPR-17-0349. Epub 2018 Feb 1.

PMID:
29437671
13.

Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization.

Yeung YT, Yin S, Lu B, Fan S, Yang R, Bai R, Zhang C, Bode AM, Liu K, Dong Z.

EBioMedicine. 2018 Feb;28:51-61. doi: 10.1016/j.ebiom.2018.01.017. Epub 2018 Feb 2.

14.

Epstein-Barr virus encoded latent membrane protein 1 suppresses necroptosis through targeting RIPK1/3 ubiquitination.

Liu X, Li Y, Peng S, Yu X, Li W, Shi F, Luo X, Tang M, Tan Z, Bode AM, Cao Y.

Cell Death Dis. 2018 Jan 19;9(2):53. doi: 10.1038/s41419-017-0081-9.

15.

Veratramine modulates AP-1-dependent gene transcription by directly binding to programmable DNA.

Bai F, Liu K, Li H, Wang J, Zhu J, Hao P, Zhu L, Zhang S, Shan L, Ma W, Bode AM, Zhang W, Li H, Dong Z.

Nucleic Acids Res. 2018 Jan 25;46(2):546-557. doi: 10.1093/nar/gkx1241.

16.

Protein activation mapping of human sun-protected epidermis after an acute dose of erythemic solar simulated light.

Einspahr JG, Curiel-Lewandrowski C, Calvert VS, Stratton SP, Alberts DS, Warneke J, Hu C, Saboda K, Wagener EL, Dickinson S, Dong Z, Bode AM, PetricoinIII EF.

NPJ Precis Oncol. 2017;1. pii: 34. doi: 10.1038/s41698-017-0037-7. Epub 2017 Sep 21.

17.

Serine 347 Phosphorylation by JNKs Negatively Regulates OCT4 Protein Stability in Mouse Embryonic Stem Cells.

Bae KB, Yu DH, Lee KY, Yao K, Ryu J, Lim DY, Zykova TA, Kim MO, Bode AM, Dong Z.

Stem Cell Reports. 2017 Dec 12;9(6):2050-2064. doi: 10.1016/j.stemcr.2017.10.017. Epub 2017 Nov 16.

18.

RSK2 phosphorylates T-bet to attenuate colon cancer metastasis and growth.

Yao K, Peng C, Zhang Y, Zykova TA, Lee MH, Lee SY, Rao E, Chen H, Ryu J, Wang L, Zhang Y, Gao G, He W, Ma WY, Liu K, Bode AM, Dong Z, Li B, Dong Z.

Proc Natl Acad Sci U S A. 2017 Nov 28;114(48):12791-12796. doi: 10.1073/pnas.1710756114. Epub 2017 Nov 13.

19.

The CUG-translated WT1, not AUG-WT1, is an oncogene.

Lee KY, Jeon YJ, Kim HG, Ryu J, Lim DY, Jung SK, Yu DH, Chen H, Bode AM, Dong Z.

Carcinogenesis. 2017 Dec 7;38(12):1228-1240. doi: 10.1093/carcin/bgx108.

PMID:
29040381
20.

A Small Molecule Inhibitor of the β-Catenin-TCF4 Interaction Suppresses Colorectal Cancer Growth In Vitro and In Vivo.

Shin SH, Lim DY, Reddy K, Malakhova M, Liu F, Wang T, Song M, Chen H, Bae KB, Ryu J, Liu K, Lee MH, Bode AM, Dong Z.

EBioMedicine. 2017 Nov;25:22-31. doi: 10.1016/j.ebiom.2017.09.029. Epub 2017 Sep 27.

21.

Herbacetin suppresses cutaneous squamous cell carcinoma and melanoma cell growth by targeting AKT and ODC.

Kim DJ, Lee MH, Liu K, Lim DY, Roh E, Chen H, Kim SH, Shim JH, Kim MO, Li W, Ma F, Fredimoses M, Bode AM, Dong Z.

Carcinogenesis. 2017 Oct 26;38(11):1136-1146. doi: 10.1093/carcin/bgx082.

PMID:
29029040
22.

A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target.

Yan F, Shen N, Pang JX, Zhao N, Zhang YW, Bode AM, Al-Kali A, Litzow MR, Li B, Liu SJ.

Leukemia. 2018 Apr;32(4):865-873. doi: 10.1038/leu.2017.307. Epub 2017 Oct 10.

23.

Lack of chemopreventive efficacy of metformin in rodent models of urinary bladder, head and neck, and colon/intestine cancer.

Thompson MD, Lubet RA, Mccormick DL, Clapper ML, Bode AM, Juliana MM, Moeinpour F, Grubbs CJ.

Oncol Lett. 2017 Sep;14(3):3480-3486. doi: 10.3892/ol.2017.6632. Epub 2017 Jul 20.

24.

APIO-EE-9 is a novel Aurora A and B antagonist that suppresses esophageal cancer growth in a PDX mouse model.

Jin G, Yao K, Guo Z, Zhao Z, Liu K, Liu F, Chen H, Gorja DR, Reddy K, Bode AM, Dong Z, Dong Z.

Oncotarget. 2017 Jun 16;8(32):53387-53404. doi: 10.18632/oncotarget.18508. eCollection 2017 Aug 8.

25.

Circulating Tumor Cells: Moving Biological Insights into Detection.

Chen L, Bode AM, Dong Z.

Theranostics. 2017 Jun 25;7(10):2606-2619. doi: 10.7150/thno.18588. eCollection 2017. Review.

26.

Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia.

Shen N, Yan F, Pang J, Zhao N, Gangat N, Wu L, Bode AM, Al-Kali A, Litzow MR, Liu S.

Clin Cancer Res. 2017 Oct 15;23(20):6254-6266. doi: 10.1158/1078-0432.CCR-17-0235. Epub 2017 Jul 18.

27.

ADA-07 Suppresses Solar Ultraviolet-Induced Skin Carcinogenesis by Directly Inhibiting TOPK.

Gao G, Zhang T, Wang Q, Reddy K, Chen H, Yao K, Wang K, Roh E, Zykova T, Ma W, Ryu J, Curiel-Lewandrowski C, Alberts D, Dickinson SE, Bode AM, Xing Y, Dong Z.

Mol Cancer Ther. 2017 Sep;16(9):1843-1854. doi: 10.1158/1535-7163.MCT-17-0212. Epub 2017 Jun 27.

PMID:
28655782
28.

LTA4H regulates cell cycle and skin carcinogenesis.

Oi N, Yamamoto H, Langfald A, Bai R, Lee MH, Bode AM, Dong Z.

Carcinogenesis. 2017 Jul 1;38(7):728-737. doi: 10.1093/carcin/bgx049.

PMID:
28575166
29.

Small molecule inhibitors of mesotrypsin from a structure-based docking screen.

Kayode O, Huang Z, Soares AS, Caulfield TR, Dong Z, Bode AM, Radisky ES.

PLoS One. 2017 May 2;12(5):e0176694. doi: 10.1371/journal.pone.0176694. eCollection 2017.

30.

PKCι is a target of 7,8,4'-trihydroxyisoflavone for the suppression of UVB-induced MMP-1 expression.

Lim TG, Kim YA, Kim JE, Baek S, Lee SY, Lee CC, Chen H, Kim JR, Kwon JY, Bode AM, Lee CY, Dong Z, Oh DK, Park JS, Lee KW.

Exp Dermatol. 2018 May;27(5):449-452. doi: 10.1111/exd.13375. Epub 2017 Jul 10.

PMID:
28453925
31.

Targeting ornithine decarboxylase (ODC) inhibits esophageal squamous cell carcinoma progression.

He W, Roh E, Yao K, Liu K, Meng X, Liu F, Wang P, Bode AM, Dong Z.

NPJ Precis Oncol. 2017 Apr 27;1(1):13. doi: 10.1038/s41698-017-0014-1. eCollection 2017.

32.

Precision medicine: the foundation of future cancer therapeutics.

Shin SH, Bode AM, Dong Z.

NPJ Precis Oncol. 2017 Apr 24;1(1):12. doi: 10.1038/s41698-017-0016-z. eCollection 2017. No abstract available.

33.

The T-LAK Cell-originated Protein Kinase Signal Pathway Promotes Colorectal Cancer Metastasis.

Zykova TA, Zhu F, Wang L, Li H, Bai R, Lim DY, Yao K, Bode AM, Dong Z.

EBioMedicine. 2017 Apr;18:73-82. doi: 10.1016/j.ebiom.2017.04.003. Epub 2017 Apr 6.

34.

Inhibiting breast cancer by targeting the thromboxane A2 pathway.

Li H, Lee MH, Liu K, Wang T, Song M, Han Y, Yao K, Xie H, Zhu F, Grossmann M, Cleary MP, Chen W, Bode AM, Dong Z.

NPJ Precis Oncol. 2017 Apr 3;1(1):8. doi: 10.1038/s41698-017-0011-4. eCollection 2017.

35.

The Prolyl Isomerase Pin1 Is a Novel Target of 6,7,4'-Trihydroxyisoflavone for Suppressing Esophageal Cancer Growth.

Lim TG, Lee SY, Duan Z, Lee MH, Chen H, Liu F, Liu K, Jung SK, Kim DJ, Bode AM, Lee KW, Dong Z.

Cancer Prev Res (Phila). 2017 May;10(5):308-318. doi: 10.1158/1940-6207.CAPR-16-0318. Epub 2017 Mar 21.

36.

Precision oncology- the future of personalized cancer medicine?

Bode AM, Dong Z.

NPJ Precis Oncol. 2017 Mar 20;1(1):2. doi: 10.1038/s41698-017-0010-5. eCollection 2017. No abstract available.

37.

TRAF1 Is Critical for DMBA/Solar UVR-Induced Skin Carcinogenesis.

Yamamoto H, Ryu J, Min E, Oi N, Bai R, Zykova TA, Yu DH, Moriyama K, Bode AM, Dong Z.

J Invest Dermatol. 2017 Jun;137(6):1322-1332. doi: 10.1016/j.jid.2016.12.026. Epub 2017 Jan 25.

38.

Neoalbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production.

Yu X, Li W, Deng Q, You S, Liu H, Peng S, Liu X, Lu J, Luo X, Yang L, Tang M, Weng X, Yi W, Liu W, Wu S, Ding Z, Feng T, Zhou J, Fan J, Bode AM, Dong Z, Liu J, Cao Y.

Mol Carcinog. 2017 May;56(5):1414-1426. doi: 10.1002/mc.22602.

PMID:
27996164
39.

Phosphorylation of NFAT3 by CDK3 induces cell transformation and promotes tumor growth in skin cancer.

Xiao T, Zhu JJ, Huang S, Peng C, He S, Du J, Hong R, Chen X, Bode AM, Jiang W, Dong Z, Zheng D.

Oncogene. 2017 May 18;36(20):2835-2845. doi: 10.1038/onc.2016.434. Epub 2016 Nov 28.

40.

Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells.

Yan F, Shen N, Pang JX, Zhang YW, Rao EY, Bode AM, Al-Kali A, Zhang DE, Litzow MR, Li B, Liu SJ.

Leukemia. 2017 Jun;31(6):1434-1442. doi: 10.1038/leu.2016.349. Epub 2016 Nov 25.

41.

Resatorvid-based Pharmacological Antagonism of Cutaneous TLR4 Blocks UV-induced NF-κB and AP-1 Signaling in Keratinocytes and Mouse Skin.

Janda J, Burkett NB, Blohm-Mangone K, Huang V, Curiel-Lewandrowski C, Alberts DS, Petricoin EF 3rd, Calvert VS, Einspahr J, Dong Z, Bode AM, Wondrak GT, Dickinson SE.

Photochem Photobiol. 2016 Nov;92(6):816-825. doi: 10.1111/php.12659. Epub 2016 Dec 8.

42.

Erratum.

Chen X, Bode AM, Dong Z, Cao Y.

FASEB J. 2016 Nov;30(11):3901. No abstract available.

PMID:
27803213
43.

A new functional IDH2 genetic variant is associated with the risk of lung cancer.

Li J, Lu J, He Y, Wu Y, Wu Y, Song X, Jiang Y, Tang M, Weng X, Yi W, Luo X, Sun L, Bode AM, Cao Y.

Mol Carcinog. 2017 Mar;56(3):1082-1087. doi: 10.1002/mc.22573. Epub 2016 Oct 24.

PMID:
27649069
44.

Four Is Better Than 1-Strength in Numbers!

Bode AM, Dong Z.

EBioMedicine. 2016 Sep;11:17-18. doi: 10.1016/j.ebiom.2016.08.046. Epub 2016 Aug 31. No abstract available.

45.

Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer.

Zhao R, Choi BY, Lee MH, Bode AM, Dong Z.

EBioMedicine. 2016 Jun;8:30-39. doi: 10.1016/j.ebiom.2016.04.017. Epub 2016 May 3. Review.

46.

Cancer prevention and control: alarming challenges in China.

Bode AM, Dong Z, Wang H.

Natl Sci Rev. 2016 Mar;3(1):117-127. Epub 2015 Aug 29.

47.

The epithelial-mesenchymal transition (EMT) is regulated by oncoviruses in cancer.

Chen X, Bode AM, Dong Z, Cao Y.

FASEB J. 2016 Sep;30(9):3001-10. doi: 10.1096/fj.201600388R. Epub 2016 Jun 8. Review. Erratum in: FASEB J. 2016 Nov;30(11):3901.

PMID:
27279361
48.

EBV-LMP1 suppresses the DNA damage response through DNA-PK/AMPK signaling to promote radioresistance in nasopharyngeal carcinoma.

Lu J, Tang M, Li H, Xu Z, Weng X, Li J, Yu X, Zhao L, Liu H, Hu Y, Tan Z, Yang L, Zhong M, Zhou J, Fan J, Bode AM, Yi W, Gao J, Sun L, Cao Y.

Cancer Lett. 2016 Sep 28;380(1):191-200. doi: 10.1016/j.canlet.2016.05.032. Epub 2016 May 30.

PMID:
27255972
49.

The Role of PGC1α in Cancer Metabolism and its Therapeutic Implications.

Tan Z, Luo X, Xiao L, Tang M, Bode AM, Dong Z, Cao Y.

Mol Cancer Ther. 2016 May;15(5):774-82. doi: 10.1158/1535-7163.MCT-15-0621. Epub 2016 Apr 15. Review.

50.

PPMP, a novel tubulin-depolymerizing agent against esophageal cancer in patient-derived tumor xenografts.

Sheng Y, Liu K, Wu Q, Oi N, Chen H, Reddy K, Jiang Y, Yao K, Li H, Li W, Zhang Y, Saleem M, Ma WY, Bode AM, Dong Z, Dong Z.

Oncotarget. 2016 May 24;7(21):30977-89. doi: 10.18632/oncotarget.9050.

Supplemental Content

Support Center